Top

Published in:

01-10-2018 | Original Research

Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing

Authors: Sarah E. Chadwell, Hua He, Sara Knapke, Jaime Lewis, Rebecca Sisson, Jennifer Hopper

Published in: Journal of Genetic Counseling | Issue 5/2018

Abstract

Genetic testing for inherited cancer risk has recently improved through the advent of multi-gene panels and the addition of deletion and duplication analysis of the BRCA genes. The primary aim of this study was to determine which factors influence the intent of individuals with a personal history of breast and/or ovarian cancer and negative or uncertain BRCA1 and BRCA2 testing to return to a hereditary cancer program for additional genetic risk assessment, counseling, and testing. Surveys were sent to 1197 individuals and 257 were returned. Of those participants who were planning to return to clinic, most cited having family members who could benefit from the test result as the primary motivation to return. Many participants who were not planning to return to clinic cited the cost of testing as a barrier to return. Cost of testing and concerns about insurance coverage were the most commonly cited barriers for the group of participants who were undecided about returning to clinic. Results from this study may be used to guide re-contact efforts by clinicians to increase patient uptake to return to clinic for up-to-date genetic risk assessment, counseling, and testing.

Available only for authorised users

Augusto, E. F., Rosa, M. L., Cavalcanti, S. M., & Oliveira, L. H. (2013). Barriers to cervical cancer screening in women attending the family medical program in Niteroi, Rio de Janeiro. Archives of Gynecology and Obstetrics, 287(1), 53–58. https://doi.org/10.1007/s00404-012-2511-3.CrossRefPubMed

Ayres, L., Kavanaugh, K., & Knafl, K. A. (2003). Within-case and across case approaches to qualitative data analysis. Qualitative Health Research, 13(6), 13.CrossRef

Castera, L., Krieger, S., Rousselin, A., Legros, A., Baumann, J. J., Bruet, O., et al. (2014). Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. European Journal of Human Genetics, 22(11), 1305–1313. https://doi.org/10.1038/ejhg.2014.16.CrossRefPubMedPubMedCentral

Bakos, A. D., Hutson, S. P., Loud, J. T., Peters, J. A., Giusti, R. M., & Greene, M. H. (2008). BRCA mutation-negative women from hereditary breast and ovarian cancer families: A qualitative study of the BRCA-negative experience. Health Expectations, 11(3), 220–231. https://doi.org/10.1111/j.1369-7625.2008.00494.x.CrossRefPubMedPubMedCentral

Buchberg, M. K., Fletcher, F. E., Vidrine, D. J., Levison, J., Peters, M. Y., Hardwicke, R., Yu, X., & Bell, T. K. (2015). A mixed-methods approach to understanding barriers to postpartum retention in care among low-income, HIV-infected women. AIDS Patient Care and STDs, 29, 126–132. https://doi.org/10.1089/apc.2014.0227.CrossRefPubMedPubMedCentral

Fecteau, H., Vogel, K. J., Hanson, K., & Morrill-Cornelius, S. (2014). The evolution of cancer risk assessment in the era of next generation sequencing. Journal of Genetic Counseling, 23(4), 633–639. https://doi.org/10.1007/s10897-014-9714-7.CrossRefPubMed

Flores, K. G., Steffen, L. E., McLouth, C. J., Vicuna, B. E., Gammon, A., Kohlmann, W., et al. (2016). Factors associated with interest in gene-panel testing and risk communication preferences in women from BRCA1/2 negative families. Journal of Genetic Counseling, 26, 480–490. https://doi.org/10.1007/s10897-016-0001-7.CrossRefPubMedPubMedCentral

Haanpaa, M., Pylkas, K., Moilanen, J.S., & Wingvist, R. (2013). Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families. BMC Medical Genetics, 14(82). http://www.biomedcentral.com/1471-2350/14/82. Accessed 28 Feb 2018.

Hampel, H. (2009). Recontacting patients who have tested negative for BRCA1 and BRCA2 mutations: how, who and why? Journal of Genetic Counseling, 18(6), 527–529. https://doi.org/10.1007/s10897-009-9254-8.CrossRefPubMed

Hiraki, S., Rinella, E. S., Schnabel, F., Oratz, R., & Ostrer, H. (2014). Cancer risk assessment using genetic panel testing: considerations for clinical application. Journal of Genetic Counseling, 23(4), 604–617. https://doi.org/10.1007/s10897-014-9695-6.CrossRefPubMed

Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Bishop, K., Altekruse, S.F., et al. (2016) SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

Judkins, T., Rosenthal, E., Arnell, C., Burbidge, L. A., Geary, W., Barrus, T., Schoenberger, J., Trost, J., Wenstrup, R. J., & Roa, B. B. (2012). Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer, 118(21), 5210–5216. https://doi.org/10.1002/cncr.27556.CrossRefPubMedPubMedCentral

Krainer, M., Silva-Arrieta, S., FitzGerald, M. G., Shimada, A., Ishioka, C., Kanamaru, R., MacDonald, D. J., Unsal, H., Finkelstein, D. M., Bowcock, A., Isselbacher, K. J., & Haber, D. A. (1997). Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. The New England Journal of Medicine, 336(20), 1416–1421. https://doi.org/10.1056/nejm199705153362003.CrossRefPubMed

Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., McGuire, V., Ladabaum, U., Kobayashi, Y., Lincoln, S. E., Cargill, M., & Ford, J. M. (2014). Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. Journal of Clinical Oncology, 32(19), 2001–2009. https://doi.org/10.1200/JCO.2013.53.6607.CrossRefPubMedPubMedCentral

Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159–174.CrossRef

Mauer, C. B., Pirzadeh-Miller, S. M., Robinson, L. D., & Euhus, D. M. (2014). The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genetics in Medicine, 16(5), 407–412. https://doi.org/10.1038/gim.2013.160.CrossRefPubMed

Minion, L., Dolinsky, J., Chao, E., & Monk, B. (2014). Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecologic Oncology, 135(2), 383–384. https://doi.org/10.1016/j.ygyno.2014.07.012.CrossRef

Moran, O., Nikitina, D., Royer, R., Poll, A., Metcalfe, K., Narod, S. A, et al. (2016). Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. Breast Cancer Research and Treatment, 1–8. doi: 10.1007/s10549-016-4038-y.CrossRefPubMed

Petrucelli, N., Daly, M. B., Pal, T. (2016). BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. 1998 Sep 4 [Updated 2016 Dec 15]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1247/.

Pratt, K. J., Collier, D. N., Walton, N. L., Lazorick, S., & Lamson, A. L. (2015). Predictors of follow-up for overweight youth and parents. Families, Systems & Health, 33, 55–60. https://doi.org/10.1037/fsh0000103.CrossRef

Susswein, L. R., Marshall, M. L., Nusbaum, R., Vogel Postula, K. J., Weissman, S. M., Yackowski, L., Vaccari, E. M., Bissonnette, J., Booker, J. K., Cremona, M. L., Gibellini, F., Murphy, P. D., Pineda-Alvarez, D. E., Pollevick, G. D., Xu, Z., Richard, G., Bale, S., Klein, R. T., Hruska, K. S., & Chung, W. K. (2016). Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genetics in Medicine, 18(8), 823–832. https://doi.org/10.1038/gim.2015.166.CrossRefPubMed

Tung, N., Battelli, C., Allen, B., Kaldate, R., Bhatnagar, S., Bowles, K., Timms, K., Garber, J. E., Herold, C., Ellisen, L., Krejdovsky, J., DeLeonardis, K., Sedgwick, K., Soltis, K., Roa, B., Wenstrup, R. J., & Hartman, A. R. (2015). Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer, 121(1), 25–33. https://doi.org/10.1002/cncr.29010.CrossRefPubMed

Vaccari, E., Yackowski, L., Hussong, M., Murphy, P., Cremona, M., Booker, J. et al. (2015). Characterizing the clinical presentation of individuals with pathogrnic variants in a breast/ovarian cancer gene panel: GeneDx.

Wevers, A., Wigboldus, D. H., de Kort, W. L., van Baaren, R., & Veldhuizen, I. J. (2014). Characteristics of donors who do or do not return to give blood and barriers to their return. Blood Transfusion, 12(Suppl 1), s37–s43. https://doi.org/10.2450/2013.0210-12.CrossRefPubMedPubMedCentral

Title: Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing
Authors: Sarah E. Chadwell
Hua He
Sara Knapke
Jaime Lewis
Rebecca Sisson
Jennifer Hopper
Publication date: 01-10-2018
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 5/2018
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-018-0241-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis

Parenting a Child with Phenylketonuria (PKU): an Interpretative Phenomenological Analysis (IPA) of the Experience of Parents

Why Patients Decline Genomic Sequencing Studies: Experiences from the CSER Consortium

Exploring the Issues Surrounding Clinical Exome Sequencing in the Prenatal Setting

Identifying Factors Underlying the Decision for Sickle Cell Carrier Screening Among African Americans Within Middle Reproductive Age

Psychosocial Impact of a Positive Gene Result for Asymptomatic Relatives at Risk of Hypertrophic Cardiomyopathy